新闻动态

学术讲座 | Development of selective irreversible BTK inhibitor

发布时间:2018-08-22    信息来源:成都先导

演讲内容:

Bruton’s tyrosine kinase (BTK) is a member of the Tec tyrosine kinase family, which is expressed in most hematopoietic cells such as B cells, myeloid cell, mast cells, and macrophage. BTK is a kinase that plays a crucial role in B-cell signaling pathway, which is an important downstream mediator of NF-κB and MAPK signaling pathways, which are strongly associated with cancer.  Therefore, BTK is a promising biological target for therapeutic intervention of autoimmune diseases and cancer/B cell malignancies.


演讲嘉宾背景介绍:


Dr. Wang graduated from Tokyo Institute of Technology in 2006 with a doctoral degree in Biomolecular Engineering. After that, he worked as a Postdoctoral researcher in Japan and USA for 6 years. Dr. Wang is currently working as a senior director of medchem in a Pharmaceutical company in Peking now.


返回列表